The classification, risk stratification, and treatment landscape in Acute Myeloid Leukemia (AML) have become increasingly complex. Since 2017 numerous drugs have been approved to treat AML, drugs that target genetic mutations (e.g., FLT3; IDH1/2), cell surface antigens (e.g., CD33), or various cell signaling transduction pathways (e.g., hedgehog pathway inhibitors; BCL-2 inhibitors).
Additionally, a variety of different modalities of drugs are currently under investigation in clinical trials for the treatment of patients with AML. These trials include CD47 targeted agents, TIM-3 inhibitors, Bispecific T-Cell Engagers, Menin Inhibitors, MDM2/HDM2 antagonists, and cellular therapies such as CAR-NKs.
Capitalizing on our unique expertise as pioneers of patient chart-based research, we offer subscriptions to our real-world data providing insights and the latest understanding of changing paradigms in the treatment of AML patients, by primary vs type of secondary AML, specific genetic mutations, fitness level, eligibility for IC; HSCT eligibility and much more. Importantly, as the classification system changes, AMLsyndiTrack also captures the physician perceptual classification vs the real-world classification (% myeloblasts) of patients with MDS vs AML-MRC.
Example of recent releases:
-
Data collected in Q1 24 in France
-
Back data available for USA, EU5, Japan, China, Canada, Austria, Switzerland, Belgium, Netherlands, Sweden...
-
Over 70 interviews of physicians (hematologists, oncologists & onco-hematologists)